Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Incidence of atazanavir- associated adverse drug reactions in second -line drugs treated south Indian HIV-1 infected patients.

Subashini D, Dinesha TR, Boobalan J, Samuel LC, Poongulali S, Pradeep A, Solomon SS, Solomon S, Balakrishnan P, Saravanan S.

Indian J Pharmacol. 2016 Sep-Oct;48(5):582-585.

2.

Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.

Gianotti N, Galli L, Poli A, Salpietro S, Nozza S, Carbone A, Merli M, Ripa M, Lazzarin A, Castagna A.

Medicine (Baltimore). 2016 May;95(22):e3780. doi: 10.1097/MD.0000000000003780.

3.

Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral Therapy.

Lin KY, Liao SH, Liu WC, Cheng A, Lin SW, Chang SY, Tsai MS, Kuo CH, Wu MR, Wang HP, Hung CC, Chang SC.

PLoS One. 2015 Sep 11;10(9):e0137660. doi: 10.1371/journal.pone.0137660. eCollection 2015.

4.

Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?

Gervasoni C, Meraviglia P, Minisci D, Ferraris L, Riva A, Landonio S, Cozzi V, Charbe N, Molinari L, Rizzardini G, Clementi E, Galli M, Cattaneo D.

PLoS One. 2015 Apr 15;10(4):e0123670. doi: 10.1371/journal.pone.0123670. eCollection 2015.

5.

HIV medication-based urolithiasis.

Izzedine H, Lescure FX, Bonnet F.

Clin Kidney J. 2014 Apr;7(2):121-6. doi: 10.1093/ckj/sfu008. Epub 2014 Mar 11. Review.

6.

Atazanavir nephrotoxicity.

Hara M, Suganuma A, Yanagisawa N, Imamura A, Hishima T, Ando M.

Clin Kidney J. 2015 Apr;8(2):137-42. doi: 10.1093/ckj/sfv015. Epub 2015 Mar 20.

7.

Clinical features and risk factors for atazanavir (ATV)-associated urolithiasis: a case-control study.

Lafaurie M, De Sousa B, Ponscarme D, Lapidus N, Daudon M, Weiss L, Rioux C, Fourn E, Katlama C, Molina JM.

PLoS One. 2014 Nov 19;9(11):e112836. doi: 10.1371/journal.pone.0112836. eCollection 2014.

8.

The New Epidemiology of HIV-Related Kidney Disease.

Mallipattu SK, Wyatt CM, He JC.

J AIDS Clin Res. 2012;Suppl 4:001.

9.

Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.

Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, Atta MG, Wools-Kaloustian KK, Pham PA, Bruggeman LA, Lennox JL, Ray PE, Kalayjian RC; HIV Medicine Association of the Infectious Diseases Society of America.

Clin Infect Dis. 2014 Nov 1;59(9):e96-138. doi: 10.1093/cid/ciu617. Epub 2014 Sep 17.

10.

Recurrent nephrolithiasis associated with atazanavir use.

Wang LC, Osterberg EC, David SG, Rosoff JS.

BMJ Case Rep. 2014 Jan 8;2014. pii: bcr2013201565. doi: 10.1136/bcr-2013-201565.

11.

Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.

Nishijima T, Hamada Y, Watanabe K, Komatsu H, Kinai E, Tsukada K, Teruya K, Gatanaga H, Kikuchi Y, Oka S.

PLoS One. 2013 Oct 10;8(10):e77268. doi: 10.1371/journal.pone.0077268. eCollection 2013.

12.

Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?

Hamada Y, Nishijima T, Komatsu H, Teruya K, Gatanaga H, Kikuchi Y, Oka S.

PLoS One. 2013 Jul 16;8(7):e69845. doi: 10.1371/journal.pone.0069845. Print 2013.

13.

Epidemiology of urolithiasis: an update.

Trinchieri A.

Clin Cases Miner Bone Metab. 2008 May;5(2):101-6.

14.

Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.

Achenbach CJ, Darin KM, Murphy RL, Katlama C.

Future Virol. 2011 Feb;6(2):157-177.

15.

Management of HIV infection in treatment-naive patients: a review of the most current recommendations.

Boyd SD.

Am J Health Syst Pharm. 2011 Jun 1;68(11):991-1001. doi: 10.2146/ajhp100156. Review.

16.

Medication-based urolithiasis and atazanavir.

Koblic PM, Gold WL, la Porte CJ, Lee TC.

CMAJ. 2011 Aug 9;183(11):E748-51. doi: 10.1503/cmaj.100019. Epub 2011 Mar 28. No abstract available.

17.

Recent developments in HIV-related kidney disease.

Estrella MM, Fine DM, Atta MG.

HIV Ther. 2010 Sep;4(5):589-603.

18.

Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients.

Alsauskas ZC, Medapalli RK, Ross MJ.

Expert Opin Pharmacother. 2011 Apr;12(5):691-704. doi: 10.1517/14656566.2011.535518. Epub 2011 Jan 21. Review.

19.

Atazanavir: its role in HIV treatment.

Wood R.

Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96. doi: 10.1586/14787210.6.6.785. Review.

20.

Acute kidney injury in HIV-infected patients.

Kalim S, Szczech LA, Wyatt CM.

Semin Nephrol. 2008 Nov;28(6):556-62. doi: 10.1016/j.semnephrol.2008.08.008. Review.

Supplemental Content

Support Center